CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Berlin, Germany and 73 other locations
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Berlin, Germany and 66 other locations
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...
Phase 3
Berlin, Germany and 188 other locations
Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...
Phase 3
Berlin, Germany and 125 other locations
This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma...
Phase 2, Phase 3
Berlin, Germany and 76 other locations
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoc...
Phase 3
Berlin, Germany and 119 other locations
cancer treatment and have also shown first encouraging results in Non-Hodgkin lymphomas. Based on these observations it is...
Berlin, Germany and 13 other locations
in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem ...
Phase 2
Berlin, Germany and 53 other locations
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this dise...
Phase 3
Berlin, Germany and 250 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Berlin, Germany and 196 other locations
Clinical trials
Research sites
Resources
Legal